IRhythm Technologies, Inc. (NASDAQ:IRTC) Receives $155.36 Consensus Price Target From Analysts
IRhythm Technologies, Inc. (NASDAQ:IRTC) Receives $155.36 Consensus Price Target From Analysts
Shares of iRhythm Technologies, Inc. (NASDAQ:IRTC – Get Rating) have received an average recommendation of "Moderate Buy" from the thirteen ratings firms that are presently covering the stock, MarketBeat.com reports. Two analysts have rated the stock with a sell rating and eight have given a buy rating to the company. The average 1-year price target among analysts that have covered the stock in the last year is $162.27.
据MarketBeat.com报道,目前涵盖iRhythm科技公司股票的13家评级公司对iRhythm Technologies,Inc.(纳斯达克代码:IRTC-GET Rating)的股票平均推荐为“中等买入”。两名分析师对该股的评级为卖出,八名分析师对该公司的评级为买入。在过去一年追踪该股的分析师中,平均1年目标价为162.27美元。
Several equities research analysts recently commented on the company. JPMorgan Chase & Co. raised their target price on iRhythm Technologies from $185.00 to $190.00 in a report on Thursday. BTIG Research upped their target price on shares of iRhythm Technologies from $155.00 to $178.00 and gave the company a "buy" rating in a research note on Friday, August 5th. Truist Financial dropped their price target on shares of iRhythm Technologies from $200.00 to $165.00 and set a "buy" rating on the stock in a research note on Thursday, June 16th. Canaccord Genuity Group upped their price objective on shares of iRhythm Technologies from $185.00 to $198.00 and gave the company a "buy" rating in a research report on Friday, September 2nd. Finally, Canaccord Genuity Group lifted their target price on iRhythm Technologies from $185.00 to $198.00 and gave the stock a "buy" rating in a research report on Friday, September 2nd.
几位股票研究分析师最近对该公司发表了评论。摩根大通在周四的一份报告中将iRhythm Technologies的目标价从185.00美元上调至190.00美元。BTIG Research将iRhythm Technologies的目标价从155.00美元上调至178.00美元,并在周五的一份研究报告中给予该公司“买入”评级。6月16日,Truist Financial将iRhythm Technologies的股票目标价从200.00美元下调至165.00美元,并在一份研究报告中对该股设定了“买入”评级。9月2日星期五,在一份研究报告中,Cancord Genuity Group将iRhythm Technologies的股票目标价从185.00美元上调至198.00美元,并给予该公司“买入”评级。最终,Cancord Genuity Group在9月2日(周五)的一份研究报告中将iRhythm Technologies的目标价从185.00美元上调至198.00美元,并给予该股“买入”评级。
Insider Transactions at iRhythm Technologies
IRhythm Technologies的内幕交易
In related news, CFO Douglas Devine sold 1,239 shares of the company's stock in a transaction that occurred on Tuesday, July 5th. The stock was sold at an average price of $108.90, for a total transaction of $134,927.10. Following the sale, the chief financial officer now directly owns 39,811 shares of the company's stock, valued at approximately $4,335,417.90. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. In related news, CFO Douglas Devine sold 1,239 shares of the firm's stock in a transaction on Tuesday, July 5th. The stock was sold at an average price of $108.90, for a total transaction of $134,927.10. Following the transaction, the chief financial officer now directly owns 39,811 shares in the company, valued at $4,335,417.90. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, EVP Daniel G. Wilson sold 1,428 shares of the firm's stock in a transaction on Tuesday, July 5th. The stock was sold at an average price of $108.93, for a total value of $155,552.04. Following the transaction, the executive vice president now owns 37,562 shares in the company, valued at $4,091,628.66. The disclosure for this sale can be found here. In the last quarter, insiders sold 12,866 shares of company stock worth $1,459,508. 1.64% of the stock is currently owned by corporate insiders.
在相关新闻中,首席财务官道格拉斯·迪瓦恩在7月5日星期二的一笔交易中出售了1,239股该公司股票。该股以108.90美元的平均价格出售,总成交金额为134,927.10美元。出售后,首席财务官现在直接持有该公司39,811股股票,价值约4,335,417.90美元。这笔交易是在提交给美国证券交易委员会的一份文件中披露的,该文件可通过此超链接。在相关新闻中,首席财务官道格拉斯·迪瓦恩在7月5日星期二的一次交易中出售了1239股该公司的股票。该股以108.90美元的平均价格出售,总成交金额为134,927.10美元。交易完成后,这位首席财务官现在直接持有该公司39,811股股票,价值4335,417.90美元。这笔交易是在提交给美国证券交易委员会的一份文件中披露的,该文件可通过美国证券交易委员会网站。此外,执行副总裁Daniel·G·威尔逊在7月5日星期二的一次交易中出售了1,428股该公司的股票。这只股票的平均售价为108.93美元,总价值为155,552.04美元。交易完成后,执行副总裁总裁现在拥有该公司37562股,价值4091628.66美元。关于这次销售的披露可以找到这里。在上个季度,内部人士出售了12,866股公司股票,价值1,459,508美元。1.64%的股份目前由企业内部人士持有。
Hedge Funds Weigh In On iRhythm Technologies
对冲基金看好iRhythm Technologies
iRhythm Technologies Trading Down 5.2 %
IRhythm Technologies股价下跌5.2%
Shares of IRTC stock opened at $122.73 on Friday. The company has a quick ratio of 3.84, a current ratio of 4.04 and a debt-to-equity ratio of 0.14. iRhythm Technologies has a fifty-two week low of $56.49 and a fifty-two week high of $169.54. The firm's 50 day moving average price is $150.09 and its two-hundred day moving average price is $138.70. The stock has a market cap of $3.69 billion, a price-to-earnings ratio of -27.77 and a beta of 1.51.
上周五,irtc的股票开盘报122.73美元。该公司的速动比率为3.84,流动比率为4.04,债务权益比率为0.14。IRhythm Technologies的股价为56.49美元,为52周低点,52周高点为169.54美元。该公司的50日移动均线价格为150.09美元,200日移动均线价格为138.70美元。该股市值为36.9亿美元,市盈率为-27.77倍,贝塔系数为1.51。
iRhythm Technologies (NASDAQ:IRTC – Get Rating) last posted its earnings results on Thursday, August 4th. The company reported ($0.79) earnings per share for the quarter, beating the consensus estimate of ($0.94) by $0.15. iRhythm Technologies had a negative net margin of 36.15% and a negative return on equity of 38.95%. The business had revenue of $102.10 million for the quarter, compared to analyst estimates of $100.51 million. During the same quarter in the previous year, the business posted ($0.59) EPS. The business's quarterly revenue was up 25.6% on a year-over-year basis. On average, analysts anticipate that iRhythm Technologies will post -3.06 EPS for the current year.
IRhythm Technologies(纳斯达克代码:IRTC-GET Rating)最近一次公布财报是在8月4日星期四。该公司公布了本季度每股收益(0.79美元),比普遍预期的(0.94美元)高出0.15美元。IRhythm Technologies的净利润率为负36.15%,股本回报率为负38.95%。该业务本季度营收为1.021亿美元,而分析师预期为1.051亿美元。在去年同一季度,该业务公布了每股收益(0.59美元)。该业务的季度收入同比增长了25.6%。分析师平均预计,iRhythm Technologies本年度每股收益将达到3.06欧元。
About iRhythm Technologies
关于iRhythm技术
(Get Rating)
(获取评级)
iRhythm Technologies, Inc, a digital healthcare company, provides ambulatory electrocardiogram (ECG) monitoring products for patients at risk for arrhythmias in the United States. It offers Zio service, an ambulatory cardiac monitoring solution that combines a wire-free, patch-based, and wearable biosensor with a cloud-based data analytic platform to help physicians to monitor patients and diagnose arrhythmias.
IRhythm Technologies,Inc.是一家数字医疗保健公司,为美国有心律失常风险的患者提供动态心电图(ECG)监测产品。它提供Zio服务,这是一种动态心脏监测解决方案,将无线、贴片和可穿戴的生物传感器与基于云的数据分析平台相结合,以帮助医生监测患者和诊断心律失常。
Recommended Stories
推荐故事
- Get a free copy of the StockNews.com research report on iRhythm Technologies (IRTC)
- MarketBeat: Week in Review 9/19 – 9/23
- Why Does Tesla Stock Remain Resilient?
- Are Layoffs At A Small-Cap Tech A Bellwether For Housing Stocks?
- Is Costco's Post-Earnings Price Weakness A Good Time To Buy?
- Will Crowdstrike Get A Boost From Increased EPS Guidance?
- 免费获取StockNews.com关于iRhythm Technologies(IRTC)的研究报告
- MarketBeat:回顾一周9/19-9/23
- 为什么特斯拉的股票保持弹性?
- 小盘股的裁员是楼市的晴雨表吗?
- 好市多盈利后价格疲软是买入的好时机吗?
- CrowdStrike是否会从增加每股收益指引中获得提振?
Receive News & Ratings for iRhythm Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for iRhythm Technologies and related companies with MarketBeat.com's FREE daily email newsletter.
接受iRhythm Technologies Daily的新闻和评级-在下面输入您的电子邮件地址,通过MarketBeat.com的免费每日电子邮件时事通讯接收iRhythm Technologies和相关公司的最新新闻和分析师评级的每日摘要。